Mission statement: The goal of Neuro-Oncology is to provide the international neuro-oncology community with high-quality, rapid publication of information in all fields. The journal welcomes submissions from throughout the world and encourages the participation of neuro-oncologists in a wide array of subspecialties. Areas covered include, but are not limited to, biochemistry and biophysics, clinical neuro-oncology, clinical therapy trials, epidemiology, imaging, immunology, medical neuro-oncology, neuropathology, molecular genetics, pediatric neuro-oncology, preclinical experimental therapeutics, retrospective clinical studies, surgical neuro-oncology, and tumor biology. Published by Oxford University Press, Neuro-Oncology is the official journal for the Society for Neuro-Oncology (SNO), the Japan Society for Neuro-Oncology, the European Association for Neuro-Oncology, and the World Federation of Neuro-Oncology Societies.

Volume 13 | Number 7 July 2011

Editorial
Evolution of Mouse Models for Studying CNS Cancer: a Decade of Progress
C. David James 691

Review
Report from the Fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop
David H. Gutmann, Charles D. Stiles, Scott W. Lowe, Gideon E. Bollag, Frank B. Furnari, and Al Charest 692

Basic and Translational Investigations
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats
Betty Tyler, Scott Wadsworth, Violette Recinos, Vivek Mehta, Ananth Vellimana, Khan Li, Joel Rosenblatt, Hiep Do, Gary L. Gallia, I-Mei Siu, Robert T. Wicks, Michelle A. Rudek, Ming Zhao, and Henry Brem 700

Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation
Ninet Azoitei, Alexander Kleger, Nina Schoo, Dietmar Rudolf Thal, Cornelia Brunner, Ganesh Varma Pusapati, Alina Flatova, Felicitas Genze, Peter Möller, Til Acker, Rainer Kuefer, Johan Van Lint, Heinrich Baust, Guido Adler, and Thomas Seufferlein 710

Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?
Luni Emdad, Zulekha A. Qadeer, Lucia B. Bederson, Harini P. Kothari, Mahmud Uzzaman, and Isabelle M. Germano 725

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence
Wanyu L. Lambiv, Eugenia Migliavacca, Marie-France Hamou, Davide Sciuscio, Raphael Burger, Eytan Domany, Roger Stupp, and Monika E. Hegi 736

Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy
Su Guan, Ruijun Shen, Tiffany Laforuntine, Ningyi Tao, Peter Houghton, W.K. Alfred Yung, and Dimpy Koul 748

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
Sylvia Ammoun, Marei Caroline Schmid, Joceline Triner, Paul Manley, and Clemens Oliver Hanemann 759

Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas—an assessment of 3 new variables in predicting clinical outcome
Linda R. Margraf, Lynn Gargan, Yasmeen Butt, Nirupa Raghunathan, and Daniel C. Bowers 767

Clinical Investigations
Peri-ictal pseudoprogression in patients with brain tumor
Sylvain Rheims, Damien Ricard, Martin van den Bent, Luc Taillander, Véronique Bourg, Virginie Desestret, Stéphanie Cartalat-Carel, Marc Hermier, Annick Monjour, Jean-Yves Delattre, Marc Sanson, Jérôme Honnorat, and François Ducray 775

Martin Dobes, Bruce Shadbolt, Vini G. Khurana, Sanjiv Jain, Sarah F. Smith, Robert Smee, Mark Dexter, and Raymond Cook 783

Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma
Fumiyuki Yamasaki, Kaoru Kurosawa, Yoshinori Kajiwara, Yosuke Watanabe, Takeshi Takayasu, Yuji Akiyama, Taiichi Saito, Ryosuke Hanaya, and Kazuhiko Sugiyama 791

News and Announcements
802